Search

Search Constraints

You searched for: Subject 616.99419

Search Results

23. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Issue 4 (3rd April 2017)

26. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. Issue 10 (24th August 2021)

27. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Issue 13 (10th November 2021)

28. A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. Issue 10 (3rd October 2018)

29. A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy. Issue 12 (December 2014)

30. A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial. Issue 7 (6th June 2020)